Table 1. Characteristics of the 125 patients with criteria for AML-MRC.
| All patients | (N = 125) | |
|---|---|---|
| N | % | |
| Median age (years, [range]) | 71 | [18-90] |
| FAB Classification | ||
| 0 | 6 | 5% |
| 1 | 13 | 10% |
| 2 | 44 | 35% |
| 4 | 25 | 20% |
| 5 | 9 | 7% |
| 6 | 9 | 7% |
| Unclassifiable | 19 | 15% |
| Previously diagnosed MDS | 59 | 47% |
| Multilineage dysplasia* | 38 | 40% |
| Cytogenetics | ||
| Normal | 28 | 22% |
| Abnormal non-complex | 55 | 44% |
| Complex | 42 | 34% |
| Monosomal | 36 | 29% |
| Non monosomal | 6 | 5% |
| MDS-related cytogenetics | 71 | 57% |
| Cytogenetic risk group | ||
| Intermediate | 65 | 52% |
| Unfavorable | 60 | 48% |
| Treatment | ||
| Intensive chemotherapy | 67 | 54% |
| Non-intensive chemotherapy | 31 | 25% |
| Demethylating agent | 19 | 15% |
| Other | 12 | 10% |
| Supportive care | 27 | 22% |
*
Multilineage dysplasia was evaluated on 94 patients
MDS = myelodysplastic syndrome